Viking Therapeutics (VKTX) Q1 2026 Earnings
VKTX·Reported April 29, 2026·After market close
Diluted EPS came in at $-1.37 (-234.1% YoY), missed the $-1.01 consensus by $0.36.
Diluted EPS
$-1.37missed by $0.36
Consensus: $-1.01
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Viking Therapeutics's Q1 2026 earnings report.
Viking Therapeutics (VKTX) reported Q1 2026 earnings on April 29, 2026 after market close.
Viking Therapeutics reported diluted EPS of $-1.37 for Q1 2026.
EPS missed the consensus estimate of $-1.01 by $0.36.
Compared to the same quarter a year prior, diluted EPS declined 234.1% from $-0.41.
You can read the 8-K earnings release (0001193125-26-191487) and the 10-Q periodic report (0001193125-26-193315) directly on SEC EDGAR. The filing index links above go to sec.gov.